Dr. Haibin Deng from the DBMR-OTM program is the first author of a study showing that LDHB suppresses mitochondria-associated ferroptosis and that its inhibition sensitizes tumor cells to radiotherapy. This study was just published in Nature Communications.

The Bill lab focuses on understanding the mechanisms of immunosuppressive communication networks in cancer and on translating predictive biomarkers for immune checkpoint inhibitors into clinical practice. Ruben Bill, MD-PhD, is an attending physician in Medical Oncology at the Inselspital, specializing in breast and head and neck cancer, as well as precision (immuno)oncology. We are delighted to have Dr. Bill joining the DBMR and wish all the success to the lab.

The PCF Challenge Award on the role of minor intron splicing in prostate cancer development led by Prof. Mark Rubin and Dr. Anke Augspach was selected as one of the highlights from the 31st Annual PCF Scientific Retreat.